Editor Profile
Dr. Ali Mohammad Alizadeh, M.Sc., Ph.D.
Associate Professor
Present
Tehran University of Medical Science (TUMS)
Tehran
Islamic Republic of Iran
Ali Mohammad Alizadeh (MSc, PhD)
Associate Professor at Tehran University of Medical Sciences
Cancer Institute
Cancer Research Center
Cancer Biology Research Center
No. 62, Gharib St., Tehran, 14194, IRAN.
Zip Code: 1419733141; Tel: 0098-21-61192798; Fax: 0098-21-66581638; Mobile: +98 912 5790941
aalizadeh@sina.tums.ac.ir; alizadehtums92@gmail.com; Website: www.pccrg.org
EDUCATION
PhD 2010 Medical Physiology Tehran University of Medical Sciences, Iran
M.Sc. 2002 Medical Physiology Tarbiat Modares University, Iran
B.Sc. 1995 Biology Golestan University of Medical Sciences, Iran
RESEARCH INTERESTS
Cancer Molecular & Therapy
Heart
PROFESSIONAL EXPERIENCES
Heart Electrophysiology in Animal Models
In vitro & In vivo Cancer Trails
Clinical and Animal Trails
THESIS
M.Sc. of Medical Physiology (2002): Role of nitric oxide on the electrophysiological properties of isolated rabbit atrioventricular node by extracellular field potential during atrial fibrillation. Score: 20 of 20; Medical School, Tarbiat Modarres University, Iran; Supervisor: Dr. Naser M.
Ph.D. of Medical Physiology (2010): Oxytocin protects cardiomyocytes from apoptosis induced by ischemia–reperfusion in rat heart: Role of mitochondrial ATP-dependent potassium channel and permeability transition pore. Score: 20 of 20; Medical School, NIGEB, Iran; Supervisor: Dr. Faghihi M.
MEMBERSHIP IN PROFESSIONAL SOCIETIES
National Foundation Elite 2010-present
Iranian Society of Physiology 2003- present
Iranian Cancer Association 2011- present
SCIENTIFIC POSITION
Associate professor, Tehran University of Medical Sciences 2018-Present.
Assistant professor, Tehran University of Medical Sciences 2013-2017.
Instructor and Board member of Cancer 2004-2013.
- Cancer Molecular & Therapy
- Heart
- F Zamani, S Khalighfard, MR Kalhori, A Poorkhani, T Amiriani Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients. Medical Oncology 2023. 40 (10), 302.
- G Vahabzadeh, S Khalighfard, AM Alizadeh, M Yaghobinejad, M Mardani. A systematic method introduced a common lncRNA-miRNA-mRNA network in the different stages of prostate cancer. Frontiers in Oncology 2023. 13, 1142275.
- S Alipour, S Khalighfard, V Khori, T Amiriani, M Tajaldini, M Dehghan. Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients. 2022. Scientific Reports 12 (1), 12054.
- M Mohsenikia, S Khalighfard, AM Alizadeh, V Khori, M Ghandian Zanjan. An innovative systematic approach introduced the involved lncRNA-miR-mRNA network in cell cycle and proliferation after conventional treatments in breast cancer patients. Cell Cycle 21 2022. (16), 1753-1774.
- S Khalighfard, MR Kalhori, T Amiriani, A Poorkhani, V Khori, E Esmati. A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy. Cancer Biomarkers 2022. 33 (1), 97-110.
- E Patrad, S Khalighfard, T Amiriani, V Khori, AM Alizadeh. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy. Cellular Oncology 2022. 45 (6), 1073-1117.
